Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 572 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH (Non-Alcoholic Steatohepatitis) Clear all
Completed Phase 2 Interventional Results available

BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH

NCT02314026
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
Suspected NASH BreathID test with 13C-Octanoate, Suspected NASH Breath test with 13C Methacetin
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Chicago, Illinois • Forts Sam Houston, Texas • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

NCT03060538
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
Interventions
BFKB8488A, Placebo
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Anniston, Alabama • Coronado, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 15, 2026, 1:34 PM EDT
Active, not recruiting Phase 2 Interventional

Statins for the Treatment of NASH

NCT04679376
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 15, 2026, 1:34 PM EDT
Withdrawn No phase listed Observational

Evaluation of Intestinal Microbiome in Obese Kids

NCT00816296
View directory record Official record
Conditions
Obesity, Non-Alcoholic Fatty Liver Disease
Interventions
Blood Draw, Stool collection, BodPod Measurement, Liver Ultrasound
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 15, 2026, 1:34 PM EDT
Recruiting No phase listed Observational

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

NCT05728697
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions
Endoscopic ultrasound shear wave elastography
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03639623
View directory record Official record
Conditions
Liver Transplant; Complications, NAFLD
Interventions
Saroglitazar
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
81
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 15, 2026, 1:34 PM EDT
Completed No phase listed Observational

Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis

NCT01324414
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Diseases (NAFLD)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 15, 2026, 1:34 PM EDT
Recruiting No phase listed Observational

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

NCT04634643
View directory record Official record
Conditions
NAFLD
Interventions
Usual diet and physical activity
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
260 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

NCT03445208
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Not applicable Interventional Results available

Obesity and Nonalcoholic Fatty Liver Disease

NCT00262964
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Niacin, fenofibrate, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

NCT02510599
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
solithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 15, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional Results available

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204
View directory record Official record
Conditions
Diabetes Complications, Fatty Liver
Interventions
exenatide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 15, 2026, 1:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

NCT02077374
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Miami, Florida • Indianapolis, Indiana • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 15, 2026, 1:34 PM EDT
Recruiting No phase listed Observational

Androgens and NAFLD Longitudinal Cohort Study

NCT06124261
View directory record Official record
Conditions
PCOS, NAFLD, NASH
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
San Francisco, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Liver - Healthy Brain

NCT05216796
View directory record Official record
Conditions
Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, NAFLD, Pre-diabetes
Interventions
Diet Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

NCT00994682
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Pioglitazone study drug, Placebo, Pioglitazone Open Label
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 15, 2026, 1:34 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 15, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons

NCT00889577
View directory record Official record
Conditions
HIV Infections, Coronary Artery Disease, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 15, 2026, 1:34 PM EDT
Completed No phase listed Observational

Vitamin D Replacement in Nonalcoholic Fatty Liver Disease

NCT03084328
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
Vitamind D
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 15, 2026, 1:34 PM EDT
Completed No phase listed Interventional Results available

Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials

NCT03611101
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device
Combination Product · Drug · Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Humble, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 15, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

NCT02633956
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Obeticholic Acid, Atorvastatin, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 15, 2026, 1:34 PM EDT
Recruiting Phase 2 Interventional

Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT06133101
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Standard Soy Milk, 2% Fat Cow's Milk
Drug
Lead sponsor
Marialena Mouzaki
Other
Eligibility
5 Years to 16 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 1:34 PM EDT